Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment

U. Flierl*, T. L. Nero, B. Lim, R. K. Andrews, M. W. Parker, E. E. Gardiner, K. Peter

*Corresponding author for this work

    Research output: Contribution to journalLetterpeer-review

    2 Citations (Scopus)

    Abstract

    Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.
    Original languageEnglish
    Pages (from-to)181-185
    Number of pages5
    JournalJournal of Thrombosis and Haemostasis
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - Jan 2018

    Fingerprint

    Dive into the research topics of 'Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment'. Together they form a unique fingerprint.

    Cite this